Home >> Research Area >> Amifostine

Amifostine

CAS# 20537-88-6

Amifostine

Catalog No. BCC5232----Order now to get a substantial discount!

Product Name & Size Price Stock
Amifostine: 5mg $863 In Stock
Amifostine: 10mg Please Inquire In Stock
Amifostine: 20mg Please Inquire Please Inquire
Amifostine: 50mg Please Inquire Please Inquire
Amifostine: 100mg Please Inquire Please Inquire
Amifostine: 200mg Please Inquire Please Inquire
Amifostine: 500mg Please Inquire Please Inquire
Amifostine: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Amifostine

Number of papers citing our products

Chemical structure

Amifostine

3D structure

Chemical Properties of Amifostine

Cas No. 20537-88-6 SDF Download SDF
PubChem ID 2141 Appearance Powder
Formula C5H15N2O3PS M.Wt 214.22
Type of Compound N/A Storage Desiccate at -20°C
Synonyms WR2721
Solubility H2O : ≥ 40 mg/mL (186.72 mM)
DMF : < 1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name 2-(3-aminopropylamino)ethylsulfanylphosphonic acid
SMILES C(CN)CNCCSP(=O)(O)O
Standard InChIKey JKOQGQFVAUAYPM-UHFFFAOYSA-N
Standard InChI InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Amifostine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Amifostine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Amifostine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.6681 mL 23.3405 mL 46.681 mL 93.362 mL 116.7025 mL
5 mM 0.9336 mL 4.6681 mL 9.3362 mL 18.6724 mL 23.3405 mL
10 mM 0.4668 mL 2.334 mL 4.6681 mL 9.3362 mL 11.6702 mL
50 mM 0.0934 mL 0.4668 mL 0.9336 mL 1.8672 mL 2.334 mL
100 mM 0.0467 mL 0.2334 mL 0.4668 mL 0.9336 mL 1.167 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Amifostine

Amifostine is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. Target: Others Amifostine has been shown to specifically protect normal tissues from damage caused by radiation and chemotherapy. An inactive prodrug, amifostine is converted to an active thiol by dephosphorylation by alkaline phosphatase in the normal endothelium. The cytoprotective mechanism of amifostine is complicated, involving free-radical scavenging, DNA protection and repair acceleration, and induction of cellular hypoxia. amifostine has potential applications in many other oncologic settings [1].

References:
[1]. Kouvaris, J.R., V.E. Kouloulias, and L.J. Vlahos, Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist, 2007. 12(6): p. 738-47.

Featured Products
New Products
 

References on Amifostine

Protective effect of amifostine on busulfan induced DNA damage in human hepatoma cells.[Pubmed:27771991]

Toxicol Mech Methods. 2017 Jan;27(1):52-57.

Busulfan is one of the most effective chemotherapeutic agents used for the treatment of chronic myeloid leukemia. However, as a bifunctional alkylating agent, during clinical use several side effects may occur. In addition, several in vivo and in vitro studies of busulfan have shown a range of genotoxic effects including DNA strand break and inhibition of DNA synthesis. Amifostine, an organic thiophosphate compound, has been shown to exert an important cyto-protective effect in many tissues. The aim of this study was to explore whether Amifostine protects against busulfan-induced genotoxicity in HepG2 cell line. Our results showed that Amifostine reduced the genotoxic effects of busulfan significantly in both type of experiment conditions, as measured via comet assay. Furthermore, Amifostine decreased the intracellular ROS generation induced by busulfan and also increased the intracellular GSH levels in HepG2 cells. Altogether, our results suggest a protective action of Amifostine against busulfan cytotoxicity and genotoxicity via various pathways. The most protective effect was observed with Amifostine when it was administrated 24 h before busulfan treatment.

CCND1-BCL2 Gene Network: A direct target of Amifostine in human acute megakaryocytic leukemia cells.[Pubmed:27762064]

Chem Biol Drug Des. 2017 May;89(5):681-693.

Amifostine, 2-(3-aminopropyl) aminoethyl phosphorothioate, is a broad-spectrum cytoprotective agent used to treat nuclear radiation and chemical weapon injuries. Recently, Amifostine has been shown to have a profound biological influence on tumor cells. To examine the effects and mechanisms underlying the effects of Amifostine on human acute megakaryocytic leukemia, we evaluated the efficacy of Amifostine against Dami cells and observed a cell cycle arrest in G2 /M phase. Amifostine treatment also induced cell apoptosis of Dami cells which corresponds to formal studies. Through whole-genome microarray and bioinformatics analyses, we found that Amifostine affected the gene expression of CCND1, BCL2, and CASP3 which revealed the mechanism Amifostine acted on Dami cells. Thus, CCND1-BCL2 Gene Network is predicted to be a direct target of Amifostine treating human acute megakaryocytic leukemia, which may provide a novel potential target for the therapy of several subtypes of human AML.

Histopathological and biochemical comparisons of the protective effects of amifostine and l-carnitine against radiation-induced acute testicular toxicity in rats.[Pubmed:28000945]

Andrologia. 2017 Nov;49(9).

The aim of this study was to compare the radioprotective efficacies of Amifostine (AMI) and l-carnitine (LC) against radiation-induced acute testicular damage. Thirty Wistar albino rats were randomly assigned to four groups: control (n = 6), AMI plus radiotherapy (RT) (n = 8), LC plus RT (n = 8) and RT group (n = 8). The rats were irradiated with a single dose of 20 Gy to the scrotal field. LC (300 mg/kg) and AMI (200 mg/kg) were given intraperitoneally 30 min before irradiation. The mean seminiferous tubule diameters (MSTDs) were calculated. Testicular damage was evaluated histopathologically using Johnsen's mean testicular biopsy score criteria. Malondialdehyde (MDA) and glutathione levels were measured in tissue samples. AMI plus RT and LC plus RT groups had significantly higher MSTDs than those in the RT group (p = .003 and p = .032 respectively). MDA values of both AMI plus RT and LC plus RT groups were significantly lower than those in RT group (p < .004 and p < .012 respectively). As a result, AMI and LC have a similar radioprotective effect against radiation-induced acute testicular damage, histopathologically and biochemically.

Sustained-release microspheres of amifostine for improved radio-protection, patient compliance, and reduced side effects.[Pubmed:27855533]

Drug Deliv. 2016 Nov;23(9):3704-3711.

A biweekly administration of sustained-release microsphere dosage form of Amifostine, a radioprotective drug used in radiotherapy, was performed to examine the feasibility to minimize injection frequency and blood concentration-associated side effects. Model animal trials indicated that this subcutaneously injecting microspheres, 50-100 mum in diameter, achieved bi-weekly prolonged radio-protective efficacy and, at the same time, significantly reduced skin irritation than the solution form of Amifostine given by the same administration route. In addition, the hypertension associated with blood concentration of Amifostine was not observed in the drug-treated rats. The animals given the Amifostine microspheres and Amifostine showed significantly differences in white blood cell, red blood cell, hematocrit, hemoglobin and spleen tissue histopathology after exposed under a cobalt-60 gamma-radiation at a dose rate of 1.0 Gy/min for 6 min. The in vitro release profile of Amifostine from the micropsheres showed a minor initial burst (less than 20% of total drug loading in the first day of administration), consisting with the side effects observations. The results suggest that Amifostine encapsulated in sustained-release microspheres may be an ideal dosage form for prolonged radio-protective efficacy and improved patient compliance.

Description

Amifostine is a broad-spectrum cytoprotection agent against the DNA damaging effects of ionizing radiation and chemotherapy drug.

Keywords:

Amifostine,20537-88-6,WR2721,Natural Products, buy Amifostine , Amifostine supplier , purchase Amifostine , Amifostine cost , Amifostine manufacturer , order Amifostine , high purity Amifostine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: